Fibrocystic Breast Disease

CHICAGO, Aug. 8, 2023 /PRNewswire/ -- In the near future, the breast biopsy devices industry is poised to witness remarkable advancements driven by innovative technologies and a growing emphasis on early detection and precise diagnosis of breast conditions. Rapid progress in imaging techniques, such as 3D mammography and molecular imaging, will catalyze the demand for minimally invasive and highly accurate biopsy devices. These devices will offer improved targeting capabilities, real-time imaging guidance, and enhanced tissue sampling methods, ultimately enhancing diagnostic accuracy and patient outcomes. Additionally, the integration of artificial intelligence and machine learning algorithms will further refine the biopsy process by providing predictive insights and aiding pathologists in analyzing tissue samples. As healthcare systems prioritize personalized medicine, the breast biopsy devices sector will play a pivotal role in revolutionizing breast health management through its convergence of cutting-edge technology and patient-centered care. Breast Biopsy Devices Market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $2.6 billion by 2028, growing at a CAGR of 10.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include the growing prevalent cases of breast cancer, the increasing number of breast cancer screening programs, the growing demand for minimally invasive and non-invasive procedures, and the improved reimbursement scenario. Download an Illustrative overview: Browse in-depth TOC on "Breast Biopsy Devices Market" 140 - Tables 45 - Figures 200 - Pages Breast Biopsy Devices Market Scope: Type segment to register significant growth rate over the forecast period of 2023-2028. Based on the type, the global breast biopsy devices market is segmented into biopsy needles, guidance systems, localization wires, assay kits, liquid biopsy instruments, biopsy tables, and other devices. The assay kits segment is expected to grow at the highest CAGR during the forecast period. In 2022, the biopsy needle segment accounted for the highest breast biopsy devices market share. Procedure segment to register significant growth rate over the forecast period of 2023-2028. Based on the procedure, the breast biopsy devices market is segmented into needle open surgical breast biopsy, breast biopsy, and liquid breast. The liquid breast biopsy segment is anticipated to register the highest growth rate over the forecast period. However, the needle breast biopsy segment accounted for the highest market share in the breast biopsy devices market in 2022. The early cancer screening segment accounted for the largest share of the breast biopsy market by application in 2022. Based on application, the market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening accounted for the largest share of the market in 2022. However, the therapy selection segment is expected to grow at the highest CAGR during the forecast period. Factors such as the rising occurrence of breast cancer cases, growing awareness of breast cancer, and supportive government initiatives for breast cancer care and treatment are expected to influence the demand for breast biopsy devices. The hospital and clinics segment accounted for the largest share of the breast biopsy devices market, by end-user, in 2022. Based on the end user, the breast biopsy devices market is segmented into hospitals & surgical centers, breast care centers, and imaging clinics & diagnostic centers. The hospitals & surgical centers segment accounts for the largest share of the market in 2022. Factors attributing to the increasing number of breast diagnostic procedures performed in hospitals, the growing inclination of hospitals toward automation and digitization of radiology patient workflow, and the rising adoption of technologically advanced systems in hospitals to improve patient care quality are driving this segment's growth. The North American market is to register significant growth in the market during the forecast period. The North American breast biopsy devices market is estimated to grow significantly from 2023 to 2028. factors such as ongoing technological advancements, rising breast cancer incidence rates, favorable reimbursement scenarios, and new breast density notification laws drive market growth in North America. This region has a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players. Request Sample Pages: Breast Biopsy Devices Market Dynamics: Drivers: Increasing number of breast cancer screening programs Restraints: Risk of infections associated with the use of biopsy needles Opportunities: Emergence of liquid biopsy and promising clinical trials Challenges: Underdeveloped Healthcare Infrastructure and Dearth of Resources in Developing Countries Key Market Players: As of 2022, prominent players in the breast biopsy devices market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Medtronic (IRL), Merit Medical Systems (US), Menarini-Silicon Biosystems (ITL), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany) and Exact Sciences Corporation (US). Recent Developments: Hologic, Inc, an innovative medical technology company primarily focused on improving women's health, announced today that it has completed the purchase of SOMATEX Medical Technologies GmbH; the deal size is $64 million. In 2022 Danaher Corporation launched Mammotome Revolve EX Dual Vacuum-Assisted Breast Biopsy System, the first vacuum-assisted biopsy device designed specifically for the excision of benign breast lesions and is twice as fast as traditional vacuum-assisted breast biopsy systems. Argon Medical Devices announced the launch of the SuperCore advantage semi-automatic biopsy instrument's newest addition to its soft tissue biopsy product portfolio in the united states. The next-generation soft tissue biopsy instrument provides a superior volume of tissue samples. Collecting more tissue volume may increase the likelihood of an accurate diagnosis. Get 10% Free Customization on this Report: Breast Biopsy Devices Market Advantages: Early Detection: Breast biopsy devices enable the early detection of suspicious lesions or abnormalities in breast tissue, allowing for prompt diagnosis and intervention. Minimally Invasive: These devices offer minimally invasive alternatives to surgical biopsies, reducing patient discomfort, scarring, and recovery time. Precision Targeting: Advanced imaging technologies incorporated in these devices allow for precise targeting of the specific area of concern, ensuring accurate tissue sampling. Reduced Procedure Time: Modern biopsy devices streamline procedures, leading to shorter procedural times, increased patient throughput, and efficient resource utilization for healthcare facilities. Improved Patient Experience: Minimally invasive procedures and shorter recovery periods contribute to a better patient experience and higher patient satisfaction rates. Cost-Effectiveness: Minimally invasive biopsies with these devices often lead to reduced healthcare costs compared to surgical alternatives, as they require fewer resources and less hospitalization time. Real-Time Imaging Guidance: Integration of real-time imaging guidance enhances the accuracy of tissue sampling and reduces the likelihood of inconclusive results. Diagnostic Accuracy: The use of advanced technologies, such as molecular imaging and artificial intelligence, enhances diagnostic accuracy, reducing the need for multiple procedures and interventions. Customized Treatment Plans: Accurate biopsy results enable healthcare professionals to create personalized treatment plans, optimizing patient care and outcomes. Research and Development: The ongoing innovation in breast biopsy device technology fuels research and development efforts, contributing to continuous improvements in diagnostic capabilities. Reduced Anxiety: Early and accurate diagnosis through these devices can alleviate patient anxiety by providing a clear understanding of their condition and appropriate treatment pathways. Screening Programs: Breast biopsy devices play a crucial role in supporting breast cancer screening programs, enabling efficient follow-up on suspicious findings from mammograms. Healthcare Resource Optimization: By reducing unnecessary surgeries and interventions, these devices help optimize the allocation of healthcare resources. Enhanced Medical Training: Modern biopsy devices are often integrated with training features, enabling medical professionals to acquire and enhance their skills in using these devices effectively. Global Impact: The widespread availability and adoption of breast biopsy devices contribute to improving breast healthcare on a global scale, especially in regions with limited access to specialized medical facilities. These advantages collectively underscore the significant role that breast biopsy devices play in improving patient care, enhancing diagnostic capabilities, and shaping the future of breast health management. Related Reports: Breast Imaging Market - Global Forecasts to 2028 Aspiration Needles Market - Global Forecasts to 2027 Liquid Biopsy Market - Global Forecasts to 2027 Cancer Diagnostics Market - Global Forecasts to 2026 Womens Health Diagnostics Market - Global Forecasts to 2025 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets

WEDNESDAY, June 14, 2023 -- Early menopause due to hysterectomy is associated with increased risks for a composite of cardiovascular disease (CVD), according to a study published online June 12 in JAMA Network Open . Jin-Sung Yuk, M.D., Ph.D., from the Inje University College of Medicine in Seoul, South Korea, and colleagues evaluated the association of hysterectomy with the risk for incident CVD among women (aged 40 to 49 years). The analysis included 55,539 pairs with and without hysterectomy matched for age, socioeconomic status, region, Charlson Comorbidity Index, hypertension, diabetes, dyslipidemia, menopause, menopausal hormone therapy, and adnexal surgery. The researchers found that during a median 7.9 years of follow-up, the incidence of CVD was 115 per 100,000 person-years for the hysterectomy group versus 96 per 100,000 person-years for the no-hysterectomy group. The hysterectomy group had an increased risk for CVD compared with the no-hysterectomy group in an adjusted analysis (hazard ratio, 1.25). While the groups were similar for the incidence of myocardial infarction and coronary artery revascularization, the risk for stroke was significantly higher in the hysterectomy group (hazard ratio, 1.31). Findings persisted even when excluding women who underwent oophorectomy. "Although we found that widely performed hysterectomy with a broad indication for benign diseases at premenopausal ages slightly increases the risk of CVD, the incidence is not high, so a change in clinical practice may not be needed," the authors write. Abstract/Full Text Posted June 2023

FN Media Group Presents USA News Group News Commentary VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX). Ahead of the SABCS, which is scheduled for December 6-10, 2022, analysts at ReportLinker are projecting that the Global Breast Cancer Therapeutics Market is expected to grow by US$13.85 billion during 2022-2026, accelerating at a CAGR of 8.95% during the forecast period. Set to present two new abstracts at the SABCS is O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) through a pair of poster presentations, including interim results from a bridging clinical trial being conducted with partners Adlai Nortye, to evaluate Oncolytics' flagship asset pelareorep in combination with paclitaxel in patients with advanced or metastatic HR+/HER2- breast cancer in one poster. The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients. Full texts of the abstracts are available on the SABCS website. Data published in the SABCS abstract indicates that pelareorep in combination with paclitaxel was safe, well tolerated, and showed anti-tumor activity in Adlai Nortye's single-arm bridging clinical trial in Chinese patients with advanced or metastatic HR+/HER2- breast cancer. As of the abstract's cut-off date, 10 patients were treated, with 4 achieving a partial response (PR) (2 confirmed, 2 unconfirmed), and 5 showing stable disease (SD). This bridging trial is designed to accelerate Adlai Nortye's development of pelareorep in China by allowing future regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND-213 and BRACELET-1. Results from IND-213 showed a statistically significant near doubling of median overall survival in HR+/HER2- breast cancer patients treated with pelareorep plus paclitaxel compared to those treated with paclitaxel monotherapy. BRACELET-1 remains ongoing, with a readout on overall response rate, progression-free survival, and evolving overall survival data from the randomized phase 2 trial expected in the first half of 2023. As for the AWARE-1 abstract, Oncolytics will be presenting results of gene expression analyses from cohorts 1 and 2, which exclusively enrolled patients with the HR+/HER2- breast cancer subtype who were treated with pelareorep and anti-cancer drug letrozole—with cohort 2 being with the PD-L1 checkpoint inhibitor atezolizumab and cohort 1 being without it. Results published in the abstract showed that the studied combinations altered tumor microenvironments to induce and enhance anti-tumor immunity. Biotech giant Eli Lilly and Company (NYSE: LLY) also announced that study investigators will present data from the company's breast cancer portfolio and pipeline at the SABCS, including new results from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]), and LOXO-783 (an investigational mutant-selective allosteric PI3Kα H1047R inhibitor). For the Verzenio oral and poster presentations, LLY will provide updated clinical data from ongoing studies in early and advanced forms of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Eli Lilly's oral presentation will provide results from a pre-planned overall survival (OS) analysis from the Phase 3 monarchE study in HR+, HER2-, node-positive, high-risk early breast cancer, including four-year efficacy outcomes. In another spotlight poster discussion, combination therapy results with imlunestrant will also be presented from the Phase 1 EMBER trial of imlunestrant in combination with Verzenio, with or without an aromatase inhibitor, in patients with estrogen receptor positive (ER+), HER2- advanced breast cancer. In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided. Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting. Oncology testing and global contract research services provider NeoGenomics, Inc. (NASDAQ: NEO) and its liquid biopsy-focused subsidiary, Inivata Limited are set to present new data at the SABCS that supports the use of their personalized, highly-sensitive sequencing test RaDaR®Assay across all types of early breast cancer in both the adjuvant and surveillance settings. "The data being presented at SABCS adds to the growing body of evidence demonstrating the accuracy of RaDaR in detecting minimal residual disease and early disease relapse," said Vishal Sikri, MBA, President and Chief Commercial Officer, Inivata, and President, Pharma Services, NeoGenomics. "We believe RaDaR offers great promise in breast cancer care as the detection of MRD and recurrence provides critical insights that can significantly impact patient care." RaDaR detects minimal residual disease (MRD) and recurrence, which are the trace amounts of circulating tumor DNA (ctDNA) that remain after surgery or other cancer treatment. One study being presented compared the use of RaDaR to digital PCR (dPCR) in the surveillance setting in 161 patients with early-stage triple-negative breast cancer (TNBC). Among ctDNA-positive patients, more than half (55.2%) were first detected by RaDaR versus 5.2% by dPCR. Clinical stage biopharmaceutical company Zymeworks Inc. (NYSE: ZYME) announced the publication of an abstract for their bispecific antibody zanidatamab, that can simultaneously bind two non-overlapping epitopes of HER2. In combination with palbociclib and fulvestrant, zanidatamab was well tolerated, with encouraging and durable anti-tumor activity in heavily pretreated patients with HER2-positive HR+ breast cancer. As per the trial, 34 heavily pretreated patients with HER2-positive HR+ breast cancer were treated with the zanidatamab+Palbociclib+fulvestrant combination, which resulted in a 34.5% confirmed objective response rate, with a 93.1% disease control rate in 29 response-evaluable patients. Commercial-stage oncology company G1 Therapeutics, Inc. (NASDAQ: GTHX) will also be presenting at SABCS with initial results from its Phase 2 Trilaciclib Mechanism of Action (MOA) Trial, which is a 24 patient trial in early-stage TNBC. G1 Therapeutics's primary endpoints will assess the immune-based MOA, including the impact of Trilaciclib on CD8+ T cells and regulatory T cells, or Tregs, in the tumor microenvironment. Secondary endpoints will include pathological complete response (pCR), immune response, and profiling measures. G1 will present initial results from the primary endpoint as a poster presentation during the 2022 SABCS. For more information please visit: Article Source: USA News Group [email protected] DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Media Contact Information: FN Media Group, LLC Media Contact e-mail: [email protected] U.S. Phone: +1(954)345-0611 SOURCE USA News Group